Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
10,710 total articles
Gadde Vijaya, a director at Planet Labs PBC, executed the sale of 20,000 Class A Common Stock shares on January 22, 2026, totaling approximately $535,350. The sale comes as the company reached significant stock price milestones and secured a notable multi-year satellite services contract with the Swedish Armed Forces. These events have prompted upw…
Eric Siemers, Chief Medical Officer of Acumen Pharmaceuticals, carried out sales of 3,226 shares of the company’s stock in late January 2026 to satisfy tax liabilities on vested restricted stock units. These transactions occurred under a Rule 10b5-1 plan and do not indicate new insider sentiment. Concurrently, Acumen continues to advance its Alzhei…
Daniel Joseph O’Connell, CEO of Acumen Pharmaceuticals, completed the sale of over 12,000 shares to satisfy tax liabilities tied to restricted stock units, under a pre-established trading plan. The company, focused on Alzheimer’s treatments, recently reported a net loss but continues progress in its clinical trials and collaboration with JCR Pharma…
Matt Zuga, Chief Financial Officer of Acumen Pharmaceuticals, completed stock sales totaling 4,160 shares valued at approximately $7,600 in late January 2026. These transactions were made to satisfy tax withholding obligations linked to vested restricted stock units, following a Rule 10b5-1 plan. Acumen remains focused on progressing Alzheimer’s tr…
On January 22, 2026, Lindblad Sven-Olof, a director and substantial shareholder of Lindblad Expeditions Holdings, Inc., sold 62,100 shares of the company's common stock, executing the transaction near the 52-week high price. The sale was conducted under a Rule 10b5-1 trading plan, generating proceeds exceeding $1 million. Amidst revenue growth and …
Derek M Meisner, Chief Legal Officer and Corporate Secretary of Acumen Pharmaceuticals, Inc., has conducted stock sales totaling $16,720 over three days in January 2026 under a pre-planned trading arrangement. These transactions come as the company continues to focus on its Alzheimer's treatment pipeline, including progressing clinical trials and c…
Aaron Tachibana, serving as CFO and COO of Personalis, Inc., engaged in significant insider transactions involving the purchase and sale of company shares on January 22, 2026. Concurrently, Personalis moves forward with Medicare reimbursement coverage for its advanced cancer monitoring tests and contemplates a sizable stock offering as it prepares …
Shannon L. Devers, Executive Vice President and Chief Human Resources Officer at Ionis Pharmaceuticals, completed a sale of nearly $323,500 worth of stock in late January 2026. The transaction occurred near the company’s 52-week high and precedes an anticipated earnings announcement. Meanwhile, Ionis continues progressing with recent regulatory app…
Chris Wren, Vice President of Operations at Planet 13 Holdings Inc, liquidated 30,000 company shares in late January 2026, amid the company's efforts to pivot its strategy following less-than-expected third-quarter earnings. Planet 13 reported $23.3 million in revenue and a negative EPS, prompting strategic exits including the California market to …
Amprius Technologies’ Chief Technology Officer, Stefan Constantin Ionel, recently sold over half a million shares totaling around $6.83 million while simultaneously exercising stock options. This activity unfolds during a period of significant stock appreciation and notable company initiatives including a new CEO transition and expanded production …
Michael F. MacLean, CFO of Avidity Biosciences Inc, executed a sale of 4,542 shares worth roughly $329,067 on January 21, 2026, in conformity with company equity incentive policies. The stock transaction occurred near its 52-week peak at $72.74 following a significant annual stock performance gain. In parallel, Avidity unveiled a Managed Access Pro…
Steven George Hughes, Chief Medical Officer at Avidity Biosciences, sold nearly 4,900 shares worth $354,642 to satisfy tax obligations related to recently vested Restricted Stock Units. This sale precedes multiple strategic developments at Avidity, including a new FDA-backed access program for its investigational muscular dystrophy therapy and an i…
W. Michael Flanagan, Chief Scientific Officer at Avidity Biosciences, recently sold 6,534 shares valued at approximately $473,388 to fulfill tax requirements related to restricted stock units. Meanwhile, Avidity is rolling out a Managed Access Program for its drug targeting Duchenne muscular dystrophy and has agreed to be acquired by Novartis in a …
On January 21, 2026, Avidity Biosciences’ President and CEO, Sarah Boyce, executed a sale of 14,387 shares in the company valued at approximately $1.04 million. The transaction, conducted near the stock's 52-week high, was performed to fulfill tax withholding on recently vested restricted stock units, as stipulated by the company's equity incentive…
On January 22, 2026, Comerica Executive Vice President James McGregor Carr completed a sale of 10,000 shares of company stock valued at roughly $980,600. This transaction occurred at prices close to the stock's annual peak and comes as Comerica pursues a merger with Fifth Third Bancorp, with recent earnings surpassing expectations.
William Radford Lovett II, a notable 10% shareholder of Dream Finders Homes, conducted a sizeable divestiture of Class A shares across two days in January 2026. These transactions unfolded while the company’s stock trades at a low price-to-earnings ratio, accompanied by a recent executive update on an expanded share repurchase plan and fresh market…
James Harry Weber, Executive Vice President of Comerica, executed significant stock sales and option exercises on January 22, 2026, coinciding with Comerica's robust stock performance and a pending merger. Despite Comerica's stock trading above its fair value and a high price-to-earnings ratio, the bank continues to demonstrate financial stability …
Rapid7's Chief Accounting Officer, Scott M. Murphy, has sold a portion of his holdings amid a significant year-over-year share price decline. The move comes ahead of an upcoming earnings report and follows mixed analyst opinions regarding the cybersecurity firm's growth prospects and valuation. Strategic initiatives including partnerships and produ…
On January 21, 2026, Argan Inc. Director Cynthia Flanders sold 19,000 shares of the company’s common stock, generating proceeds of approximately $7.35 million. Following this sale, Flanders remains a shareholder with a stake of 26,207 shares. Concurrently, Argan Inc. reported its fiscal third-quarter earnings, posting earnings per share surpassing …
Craig W. Kliethermes, CEO of RLI Corp, increased his ownership by acquiring 5,000 shares valued at $287,250 in late January 2026. This move comes alongside the company's recently announced fourth-quarter 2025 financial results, which showed earnings per share surpassing forecasts yet revenue falling short. Analysts present a range of perspectives o…
Gregory James Quarles, CEO Emeritus of Applied Energetics Inc., carried out a share sale along with exercising stock options on January 21, 2026. Concurrently, the company made notable strides by being selected for the Missile Defense Agency’s SHIELD program and adding Dr. Matthew Seaford to its Advisory Board, emphasizing growth in the defense and…
Yelp Inc.'s CEO Jeremy Stoppelman recently divested $2.59 million worth of company shares while simultaneously exercising stock options and maintaining a substantial personal stake. These moves took place amid shares trading close to their 52-week low, below analyst valuations, even as Yelp posted earnings surpassing expectations and pursued strate…
Brett Schulman, CEO and President of Cava Group Inc., sold 21,650 shares valued around $1.46 million to fulfill tax withholding obligations linked to vested restricted stock units. Despite fluctuations in stock price and varying analyst projections, the company maintains strong profitability and liquidity fundamentals while announcing a key executi…
Theodoros Xenohristos, Director and Chief Concept Officer of Cava Group, Inc., divested 965 shares on January 21, 2026, primarily to cover tax obligations. This sale comes during a period where Cava's stock has experienced declines over the past six months, although it remains above its 52-week low. Despite market volatility, the company maintains …
Novanta Inc.'s CEO, Matthijs Glastra, executed a significant stock sale in January 2026, disposing of 7,500 shares at $140 each, amounting to $1.05 million. This transaction occurred as the company's shares demonstrated considerable upward momentum despite trading below their 52-week peak. Concurrently, Novanta revised its earnings forecasts amid a…
